老人頭暈、疲勞、骨疼可能是多發性骨髓瘤！癌症希望基金會與台大血液科26日首次公布「多發性骨髓瘤癌友及家屬癌後生活需求」研究結果，台大血液科醫師黃聖懿表示，多發性骨髓瘤是國內發生率第三高的血癌，但1/4存活期超過10年，鼓勵癌友積極治療。癌症希望基金會副執行鄭凱芸也建議衛福部，應改進電子病歷便利性，並擴大健保給付用藥類別上限，讓癌友治療無慮。
鑒於台灣人口高齡化，好發在65-70歲的多發性骨髓瘤病友卻常因症狀與慢性病類似，不僅易延誤治療，癌症帶來的貧血、疼痛、行動不便會讓病友生活品質低、社交隔閡，甚至失去求生慾望。對此，癌症希望基金會與台大血液科公布「多發性骨髓瘤癌友及家屬癌後生活需求」研究結果，鼓勵病友善用社區抗癌資源、改善生活品質，並建立正向目標。
黃聖懿說，多發性骨髓瘤是國內發生率第三高的血癌，年新增患者約500人，根據台大醫院過去統計1000名患者就醫原因，以骨痛與骨折最常見。從2007年後，多發性骨髓瘤的死亡率逐年降低，因為近十年新藥問世，藉由不同藥物組合搭配移植，患者存活率延長至5-7年，甚至1/4超過10年。黃聖懿說，健保署2018年也通過後線口服藥物給付，鼓勵癌友積極治療。
鄭凱芸表示，此為國內第一個針對多發性骨髓瘤患者社會與心理支持研究，報告指出，多發性骨髓瘤患者生理上的不適對生活造成嚴重困擾，包括藥物副作用、行動力降低。同時照顧者也承受壓力，包含過多醫療資訊轟炸、醫病溝通的有限性，以及對死亡的擔心。
針對實務工作的改善，鄭凱芸提出嚴密監控病人疼痛、關注照顧者需求、提供科技整合的照顧模式、專業講座填補醫病溝通缺口4項建議。鄭凱芸更建議，衛福部應改進電子病歷便利性，並擴大健保給付用藥類別上限，讓癌友治療無慮。
Old people dizziness, fatigue, bone pain may be multiple myeloma! The Cancer Hope Foundation and the Department of Hematology of National Taiwan University announced on the 26th the results of the study on the needs of post-cancer life of multiple myeloma cancer patients and their families. According to Huang Shengyu, a neurologist at National Taiwan University, multiple myeloma is the third highest incidence of blood cancer in China. However, 1/4 survival period is more than 10 years, encouraging cancer patients to actively treat. Zheng Kaixuan, deputy executive of the Cancer Hope Foundation, also suggested that the Department of Health and Welfare should improve the convenience of electronic medical records and expand the upper limit of the type of health care payment for cancer patients to treat.
In view of the aging population in Taiwan, multiple myeloma patients who are 65-70 years old often have similar symptoms and chronic diseases. They are not only prone to delay in treatment. The anemia, pain and inconvenience caused by cancer will make the patients' quality of life low and social. Separation, even lost the desire to survive. In response, the Cancer Hope Foundation and the Department of Hematology of the National Taiwan University announced the results of the study on the needs of patients with multiple myeloma cancer and family members after cancer, encouraging patients to make good use of community cancer resources, improve their quality of life, and establish positive goals.
Huang Shengqi said that multiple myeloma is the third highest incidence of blood cancer in China. The number of new patients is about 500. According to the statistics of 1,000 patients in the past, the majority of patients with bone pain and fractures are the most common. Since 2007, the mortality rate of multiple myeloma has been decreasing year by year. Because of the emergence of new drugs in the past decade, the survival rate of patients has been extended to 5-7 years, even 1/4 more than 10 years, through different drug combinations. Huang Shengqi said that the Health Insurance Agency also passed the oral drug payment in the back line in 2018 to encourage cancer patients to actively treat.
Zheng Kaixuan said that this is the first social and psychological support study for patients with multiple myeloma. The report pointed out that the physical discomfort of patients with multiple myeloma is seriously plagued by life, including drug side effects and reduced mobility. At the same time, caregivers are under pressure, including excessive medical information bombing, limited medical and medical communication, and fear of death.
In response to the improvement of practical work, Zheng Kaiwei proposed four recommendations to closely monitor patient pain, pay attention to the needs of caregivers, provide a model of care for scientific and technological integration, and provide professional lectures to fill the gap in medical communication. Zheng Kaixuan also suggested that the Department of Health and Welfare should improve the convenience of electronic medical records and expand the upper limit of the types of health care payment drugs, so that cancer patients can be treated without care.
Laennec is the ethical drug manufactured with JBP’s unique technologies.
Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver. Our product safety is ensured by the most rigid safety measures among existing scientific standards.
留言列表
